HongKong:1672

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

HANGZHOU and SHAOXING, China, March 10, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of...

2024-03-11 08:10 1007

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University. This P...

2024-01-24 16:50 1365

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis -  Primary efficacy endpoints: * NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD A...

2024-01-23 12:17 1253

Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet --At Week 12, up to 93.3% patients achieved at least a 30% relative reduction in liver fat content from baseline ...

2024-01-02 20:06 1694

Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects --The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National Medical Products Administration and obtained the approval from Institutional Review Board of Hu...

2023-12-05 16:50 1446

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB), and abst...

2023-11-13 08:10 1836

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr.Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held atBoston, Unit...

2023-11-09 08:10 4053

Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the safety, pharmacokinetics (PK), and pharmacodynamics (PD) data of ASC42, a novel farnesoid X receptor (FXR) agonist, in healthy subjects ha...

2023-11-06 12:20 1434

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023

HANGZHOU and SHAOXING, China, Oct. 11, 2023  /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Der...

2023-10-11 08:10 1684

Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of ch...

2023-09-29 08:10 2092

Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

--Based on prespecified interim analysis condition, 120 patients are likely to lead sufficient events for interim analysis of progression-free survival (PFS) HANGZHOU and SHAOXING, China, Sept. 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the completion o...

2023-09-26 08:10 1700

Ascletis to Participate in the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

HANGZHOU and SHAOXING, China, Sept. 5, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference.John Gargiulo, Chief Business Officer of Ascletis, will join the fireside chat...

2023-09-05 08:10 1609

Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science

HANGZHOU and SHAOXING, China, July 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Shanghai Public Health Clinical Center presented clinical results of ASC22 (Envafolimab) in combination with Chidamide for functional cure of human immunodeficiency virus...

2023-07-25 08:10 1751

Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis

-- Gannex is expected to release topline data of the Phase II clinical trial by the end of 2023 SHANGHAI, July 20, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today the completion of enrollment of 98 patients with ...

2023-07-20 08:10 2083

Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023

HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (...

2023-06-26 08:10 2562

Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed that ...

2023-05-08 16:50 2382

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ASC40 (Denifanstat), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, achieved primary and key secondary endpoints in Phase II clinical trial for acn...

2023-05-02 17:30 2749

Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index

HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the Hang Seng Hong Kong-Listed Biotech Index (Index code: HSHKBIO), effective from March 13, 2023. HSHKBIO selects securities of multiple listed co...

2023-02-27 17:15 2463

Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023

--At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's --ASC10 at 800 mg, BID is safe and well tolerated --Dosage of 800 mg ASC10, BID was selected for Phase IIa clinical trial for respiratory syncytial virus (RSV) inf...

2023-02-21 08:10 2292

Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the Liver ("APASL Annual Meeting 2023") demonstrates that ASC22 (Envafol...

2023-02-16 17:10 2713
12345 ... 8

Week's Top Stories